This isn't Jack O'Meara's first rodeo.

As CEO of Ochre Bio, he saw the company bring in millions to develop pioneering RNA therapies for liver disease. With his new venture Aerska, he's looking at bringing the transformative potential of targeted RNA therapy to the realm of neurological disease.

In this episode of A Call to Lead, David Kirk speaks with Jack O’Meara, CEO and co-founder of Aerska, about his personal story behind tackling neurodegenerative disease and the realities of leading biotech companies in Europe.

Jack shares candid lessons on decision-making, context-driven leadership, and building transatlantic networks to scale innovation.

Biotech leader Avencia Sánchez-Mejías, CEO of Integra Therapeutics, joins A Call to Lead to share her leadership and entrepreneurship story, as well as her take on innovation in Europe’s fast-rising life sciences ecosystem.

In this episode of A Call To Lead, Avencia shares lessons on resilience, uncertainty, diversity, and the human side of leadership in science-driven entrepreneurship. Listen to her journey from academia to biotech CEO, her vision for safer gene editing, and how resilient leadership is reshaping European biotechnology.

How do you lead a company across continents and through uncertainty?

In this episode of A Call to Lead, David Kirk speaks with Samir Ounzain, CEO and scientific co-founder of Haya Therapeutics.

Samir shares how a lifelong curiosity about how cells “speak” to their environment led him from academia to building a company at the frontier of RNA-guided medicine.

He reflects on what it takes to lead through uncertainty, translate visionary science into tangible therapies, and build culture and alignment across continents. This conversation is a masterclass in marrying deep biology with purposeful leadership.